Last reviewed · How we verify
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Candesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
Details
| Lead sponsor | EMS |
|---|---|
| Phase | Phase 3 |
| Status | WITHDRAWN |
| Start date | 2016-11 |
| Completion | 2017-08 |
Conditions
- Essential Arterial Hypertension
Interventions
- Candesartan + Chlorthalidone (8mg+12,5mg)
- Candesartan + Chlorthalidone (8 mg + 25 mg)
- losartan+hydrochlorothiazide
Primary outcomes
- Efficacy of essential hypertension control based on proportion of participants who achieve the therapeutic goal — 60 days